首页> 外文OA文献 >A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

【2h】

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

机译：Selumetinib（AZD6244，Arry-142886）的II期评价，一种选择性MEK-1/2抑制剂，治疗复发或持续的子宫内膜癌：NRG肿瘤学/妇科肿瘤学群体研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Robert L. Coleman; Michael W. Sill; Premal H. Thaker; David P. Bender; Daron Street; William P. McGuire; Carolyn M. Johnston; Jacob Rotmensch;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study [J] . Coleman Robert L., Sill Michael W., Thaker Premal H., Gynecologic Oncology: An International Journal . 2015,第1期

机译：选择性药物MEK-1 / 2抑制剂selumetinib（AZD6244，ARRY-142886）的II期评估：NRG肿瘤/妇科肿瘤小组研究
2. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J] . Coleman Robert L., Sill Michael W., Bell-McGuinn Katherine, Gynecologic Oncology: An International Journal . 2015,第3期

机译：NRG肿瘤/妇科肿瘤小组研究对有效，高度选择性的PARP抑制剂veliparib进行II期评估，以治疗携带种系BRCA1或BRCA2突变的患者持续或复发的上皮性卵巢癌，输卵管或原发性腹膜癌
3. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: A An NRG Oncology/Gynecologic Oncology Group Study 0229N [J] . Makker Vicky, Filiaci Virginia L., Chen Lee-may, Gynecologic Oncology: An International Journal . 2015,第1期

机译：dalantercept的II期评估，一种可溶的重组激活素受体样激酶1（ALK1）受体融合蛋白，用于治疗复发性或持续性子宫内膜癌：NRG肿瘤/妇科肿瘤研究0229N
4. Sodium selenite in gynecologic radiation oncology. Results of a phase III study [C] . Muecke, R., Glatzel, Workshop on Macro, Trace and Ultratrace Elements; 20040924-25; Jena(DE) . 2004

机译：亚硒酸钠在妇科放射肿瘤学中的应用。第三阶段研究的结果
5. A phase II evaluation of selumetinib (AZD6244 ARRY-142886) a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study [O] . Robert L. Coleman, Michael W. Sill, Premal H. Thaker, -1

机译：选择性药物MEK-1 / 2抑制剂selumetinib（AZD6244ARRY-142886）的II期评估：NRG肿瘤/妇科肿瘤小组研究
6. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study [O] . Bender, David, Sill, Michael W., Lankes, Heather A., 2015

机译：西地那尼治疗复发性或持续性子宫内膜癌的II期评估：NRG肿瘤/妇科肿瘤小组研究

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

著录项

相似文献

相关主题

期刊订阅